Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Seimetz, Diane Lindhofer, Horst Bokemeyer, Carsten 2010 - Forschungsinformationssystem des UKE